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Hydrocephalus is a common brain disorder that is treated 
only with surgery. The basis for surgical treatment rests on 
the circulation theory. However, clinical and experimental 
data to substantiate circulation theory have remained in-
conclusive. In brain tissue and in the ventricles, we see that 
osmotic gradients drive water diffusion in water-perme-
able tissue. As the osmolarity of ventricular CSF increases 
within the cerebral ventricles, water movement into the 
ventricles increases and causes hydrocephalus. Macromo-
lecular clearance from the ventricles is a mechanism to 
establish the normal CSF osmolarity, and therefore ven-
tricular volume. Efflux transporters, (p-glycoprotein), are 
located along the blood brain barrier and play an impor-
tant role in the clearance of macromolecules (endobiotics 
and xenobiotics) from the brain to the blood. There is clini-
cal and experimental data to show that macromolecules 
are cleared out of the brain in normal and hydrocephal-
ic brains. This article summarizes the existing evidence to 
support the role of efflux transporters in the pathogenesis 
of hydrocephalus. The location of p-gp along the pathways 
of macromolecular clearance and the broad substrate 
specificity of this abundant transporter to a variety of dif-
ferent macromolecules are reviewed. Involvement of p-gp 
in the transport of amyloid beta in Alzheimer disease and 
its relation to normal pressure hydrocephalus is reviewed. 
Finally, individual variability of p-gp expression might ex-
plain the variability in the development of hydrocephalus 
following intraventricular hemorrhage.
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Hydrocephalus is a common brain disorder that affects chil-
dren and individuals of all ages. It is the most common con-
genital abnormality in children (one out of 500 births) (1). If 
left untreated, hydrocephalus can lead to permanent brain 
damage and result in cognitive and physical handicap.
Contemporary surgical management of hydrocephalus 
is based on the popular conceptualization of circulation 
theory. The circulation theory of hydrocephalus states that 
cerebrospinal fluid (CSF) produced by the choroid plexus 
flows along specific pathways to be absorbed by the ve-
nous sinuses. An obstruction in any part of these pathways 
leads to hydrocephalus. Surgical management of hydro-
cephalus is therefore directed at detecting and removing 
the source of obstruction (such as removal of tumor or 
blockage of pathways) or diverting the fluid bypassing the 
obstruction. As such, the most common treatment for hy-
drocephalus is the surgical implantation of a shunt system 
to divert the flow of CSF from the ventricles. However, al-
though most cases of hydrocephalus are managed with a 
shunt system, it is rare for the device to last a lifetime with-
out complications. Treatment of hydrocephalus leads to 
approximately 38 000 admissions per year in the US. Costs 
for treatment range from US $1.4-2 billion per year and ap-
proximately US $1 billion is spent on the revision of mal-
functioning shunts (2).This may be a result of poor shunt 
design or a flawed approach to treatment.
Circulation theory rests on the assumption that the brain 
parenchyma is impermeable to water, and is therefore in-
capable of independently absorbing the CSF that accumu-
lates in the ventricles. However, we have previously seen 
that the brain is, in fact, permeable to water due to the 
presence of aquaporin channels and other ion channels 
(3,4). This permeability of brain parenchyma to water and 
several other observations question the validity and appli-
cability of circulation theory to design treatment strategies 
for hydrocephalus.
In brain tissue and in the ventricles, we see that osmotic 
gradients drive water diffusion in water permeable tissue. 
Alteration in osmolarity resulting from increase in the con-
centration of macromolecules and ions has been shown to 
increase the fluid content and hence the size of the ventri-
cles (5-7). Any osmotic gradient between the ventricular or 
interstitial CSF and the blood is equilibrated with transport 
of water between the two compartments. Therefore, water 
movement into the ventricle is secondary to the presence 
of osmotic gradients due to excess macromolecules. Thus, 
water movement into and out of the ventricles is not inde-
pendent but is dependent upon the presence and resolu-
tion of osmotic gradients due to increase or decrease in 
the macromolecular content (8).
Within this article, we review the role played by osmotic 
gradients and macromolecular ventricular clearance in hy-
drocephalus. Macromolecular clearance from the ventri-
cles is a mechanism to establish the normal CSF osmolar-
ity, and therefore ventricular volume. At least two primary 
pathways of macromolecular ventricular clearance have 
been studied: paravascular pathways (also known as glym-
phatic pathways) and olfactory lymphatic pathways.
In particular, we focus on the role played by efflux trans-
porters, specifically p-gp (ABC-B1) in the pathogenesis of 
hydrocephalus. Efflux transporters are responsible for the 
transport and clearance of both endogenous (endobiotics) 
and exogenous (xenobiotics) substances. An understand-
ing of these transporters is critical to designing effective 
pharmacological treatment for this problematic disorder.
OSMOTIC GRADIENT AND ITS ROLE IN 
HYDROCEPHALUS
Previously, hydrocephalus was thought to be a result of an 
imbalance between CSF production by the choroid plexus 
and absorption of CSF into the venous sinuses (9,10), Clini-
cal and experimental data to substantiate circulation theo-
ry have remained inconclusive (11).
One of the fundamental assumptions of the circulation 
theory is that the brain parenchyma is impermeable to CSF, 
and is therefore incapable of absorbing the CSF accumulat-
ing within the ventricles. However, the brain parenchyma 
is permeable to water (12). The molecular basis of this per-
meability involves specific ion channels that permit water 
movement with ions as well as aquaporin channels, which 
permit the free movement of water without changing the 
ionic environment (3). Aquaporin channels are membrane 
proteins that have an ion trap and allow movement of wa-
ter without allowing movement of ions. Several aquaporin 
channels (aquaporins 1, 4, and 9) are found in the brain 
tissues (13-15). Aquaporin 4 (AQP4) channels are found in 
the ependymal cells lining the lateral ventricles and on the 
end feet of astrocytes. These astrocytes, in particular, con-
tact microvessels in the periventricular white matter and 
the subpial region of the cerebral cortex (4). The distribu-
tion of AQP4 within the brain suggests that water free-
ly moves through the brain parenchyma between the 
ventricles and vascular system.
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As a consequence of water permeability in the brain tis-
sues, osmotic gradients are established by the presence of 
relatively impermeable, regulated solutes in the ventricles. 
These gradients result in water transport from the blood 
plasma into the ventricular CSF (5,6). Driven by osmotic 
and hydrostatic gradients, water moves between blood 
plasma and CSF as blood flows through the microvascu-
lature (7,11,16). Therefore, as the osmolarity of ventricular 
CSF increases within the cerebral ventricles, water move-
ment into the ventricles increases, causing hydrocephalus.
Clinically, high levels of proteins such as thrombopoietin 
(17), ferritin (18), nerve growth factor (19), chondroitin sul-
fate proteoglycan (20), transforming growth factor beta 
1 (21,22), transforming growth factor beta 2 (20), S-100 
protein (23,24), glial fibrillary acidic protein (GFAP) (24), 
neuron specific enolase (NSE) (24), myelin basic protein 
(MBP) (24), and vascular endothelial growth factor (25) 
within ventricular CSF, which may contribute to an eleva-
tion in osmolarity, have been observed in patients with 
hydrocephalus. Additionally, it has been shown that brain 
edema results from hyponatremia, which is evidence that 
there is free movement of water from the plasma into the 
brain tissue (26).
There is substantial experimental evidence relating the 
osmolarity of the CSF to hydrocephalus. Evidence that in-
crease in CSF osmolarity leads to an increase in ventricular 
volumes has recently been shown through experiments 
in our laboratory. Dextran infused into the ventricles of 
rat brains in vivo over 12 days resulted in hydrocephalus, 
with increasing levels of CSF osmolarity corresponding to 
proportional increase in ventricle volume (5,6). In other 
experiments, infusion of proteins FGF-2 (27) and throm-
bin (28) into the ventricles of animals led to the dilation of 
ventricles. Other investigators have confirmed the pivotal 
role that osmotic gradients play in the enlargement of the 
ventricles and development of hydrocephalus (29-31). A 
recent study demonstrated significantly faster entry of wa-
ter from the blood plasma into the CSF with acute increase 
in CSF osmolarity, which subsequently led to an increase 
in intracranial pressure (7). These facts suggest that fluid 
transport from and to the ventricles is secondary to solute 
or macromolecular transport.
PATHWAYS FOR CLEARANCE OF MACROMOLECULES
Since osmotic gradients result in hydrocephalus and 
are caused by the presence of macromolecules in the 
ventricles, it is particularly important to understand 
ventricular clearance of macromolecules. We found that 
macromolecules infused into the ventricles are cleared 
through the brain parenchyma along the perivascular 
spaces and along the cribriform plate into the nose (pa-
per being submitted for publication).These findings are 
consistent with the results of other authors (32-35). Ren-
nels et al infused horseradish peroxidase (HRP) into the 
lateral ventricles and found that there was a rapid para-
vascular influx of HRP – a faster influx than can be expect-
ed from diffusion (33). The same group found that this 
transport of HRP through the paravascular pathways was 
limited by focal cerebral edema (36). Zhang et al injected 
India ink into cerebral white and gray matter and into the 
subarachnoid space and found that the tracer was trans-
ported along specific paravascular pathways (37). Further, 
subarachnoid injection resulted in transport of the tracer 
along the paravascular pathways as well as through the 
lymphatics in the nose. The observation that macromol-
ecules or tracers in the ventricles are transported along 
paravascular pathways has been recently confirmed by 
observing the tracer movement using confocal micros-
copy (38) and magnetic resonance (MR) imaging (39).
These pathways have been referred to as the glymphatic 
pathways or system (38,39). Zhang et al found that the 
particulate matter that was injected was rapidly and ef-
ficiently ingested by perivascular cells (37). These authors 
highlighted both the paravascular and the nasal lym-
phatic pathways in macromolecular clearance and their 
immunological significance (38).
LOCATION AND FUNCTION OF EFFLUX TRANSPORTERS
The regulation of transport of macromolecules into and 
out of the brain is vital to maintaining homeostasis and en-
suring a proper environment for neural activity. There are 
a number of both endobiotic and xenobiotic compounds 
(Table 1) that have been documented to be cleared from 
the brain at the blood-brain barrier (BBB). Efflux trans-
porters are located along the blood-brain barrier as well 
as blood-CSF barrier (BCSFB) and play an important role 
in maintaining homeostasis of compounds and solutes in 
the brain milieu as well as the CSF (40). The brain capillary 
endothelial cells form a tight barrier and are characterized 
by the absence of any fenestrations (41). These anatomi-
cal features of the BBB restrict the paracellular leakage of 
endogenous or exogenous compounds from the brain 
into the capillaries (42). As a result, transcellular transport 
across the BBB and subsequent clearance by these efflux 
transporters is critical in the elimination of unwanted sol-
utes from the brain (41). The two important classes of ac-
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tive efflux transporters on the BBB are the solute transport-
er carrier family (SLC) (this family includes organic anion 
transporting polypeptides [OATP/SLCO] and organic an-
ion transporters [OAT/SLC22A]) and ATP-binding cassette 
(ABC) transporters, in particular multidrug resistance-asso-
ciated proteins and p-gp (41).
Members of the ABC transporter family, which include 
p-gp, MRP 1-6, and BRCP, have been shown to eliminate 
an abundance of macromolecular substrates from the 
brain including anticancer drugs, immunosuppression 
drugs, corticoids, analgesics, HIV protease inhibitors, cy-
tokines, antidepressants, antibiotics, and diagnostic dyes, 
such as Rhodamine-123, just to name a few (43). Barbi-
turates, many of which are p-gp substrates (44), injected 
into the CSF compartments of dogs are rapidly cleared 
into the bloodstream (45). Cholecystokinin-A (CCK-A) and 
CCK-B have both been shown to be p-gp substrates (46). 
One study found that intraventricular injection of CCK-A 
led to less feeding in rats, presumably being cleared into 
the bloodstream and interacting with peripheral recep-
tors (47).
Xenobiotics and other endobiotics are recognized by xe-
nobiotic sensors also known as adopted “orphan” nuclear 
receptors (pregnane X receptor [PXR] and constitutive an-
drostane receptor [CAR]) in the cytoplasm (48). Both nucle-
ar receptors can be activated by endogenous ligands and a 
wide range of xenobiotics (49), which include a broad array 
of prescription drugs, herbal remedies, steroid hormones, 
bile salts, and vitamins (50). These nuclear receptors can 
then up-regulate the functional expression of p-gp (51). 
Inhibition of PXR and CAR activities could reduce p-gp ex-
pression, whereas activation of PXR and CAR can induce 
p-gp expression (50).
P-gp expression on the plasma membranes of the brain 
capillary endothelial cells (on the luminal or blood-side of 
the endothelial cell), pericytes, and astrocytes show that 
p-gp is expressed in all cells that make up the BBB (52).The 
paravascular pathways may clear macromolecules through 
the BBB, particularly by using efflux transporters located 
on the BBB (38). Specifically, p-gp is of great interest in 
this role due to the fact that it is the most abundant efflux 
transporter on the BBB and has broad substrate specific-
ity (53). In addition, p-gp transporters are distributed along 
the pathways of the macromolecular clearance explained 
above, along the microvessels in the thalamus, hippocam-
pus, cerebellar, and cerebral cortex from 22 weeks of gesta-
tion to adulthood (54). Therefore, we are going to focus the 
discussion on the role played by efflux transporters with a 
special emphasis on p-gp.
P-GLYCOPROTEIN AND ITS ROLE IN THE 
PATHOPHYSIOLOGY OF HYDROCEPHALUS
We hypothesize that impaired macromolecular clearance 
out of the brain will result in increased concentration of 
endobiotics or xenobiotics in the brain interstitium and 
ventricular fluid. This change will result in water in-
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flux into the ventricles resulting in hydrocephalus. Optimal 
efflux transport and clearance of macromolecules prevents 
the development of hydrocephalus. Down-regulation or 
inhibition of the efflux transport will result in hydrocepha-
lus, while up-regulation of the efflux transport will relieve 
hydrocephalus. We will examine the current evidence that 
supports this concept.
Inhibition and induction of p-gp has been shown to affect 
the amount of substrates that remain within the brain or 
enter it. Induction of p-gp at the BBB has been shown to 
decrease the concentration of such substrates in the brain 
extracellular fluid (55-59). Conversely, inhibition of p-gp on 
the BBB has been shown to increase substrate concentra-
tions in the brain (60-64). Several studies point to the pos-
sible role of p-gp in diseases of the central nervous sys-
tem including Alzheimer disease (65,66), Parkinson disease 
(65,66), Huntington’s disease (66), Creutzfeldt-Jakob’s dis-
ease (66), amyotrophic lateral sclerosis (66), and epilepsy 
(66). The role that p-gp plays in numerous neurodegenera-
tive diseases is believed to be in part due to the protection 
that it provides at the BBB to maintain homeostasis in the 
brain and protect it against toxic compounds. Its function 
along the BBB is believed to prevent the accumulation of 
potentially harmful compounds in the brain by actively re-
moving them into the peripheral circulation (67).
The importance of macromolecular clearance in main-
taining normal neurological function is exemplified by the 
pathophysiology of Alzheimer disease. Normally amyloid-β 
is cleared from the brain via efflux transporters on the BBB, 
particularly by p-gp and MRP1 (68). When amyloid-β is 
insufficiently cleared from the brain, toxic Aβ oligomeric 
and aggregated species accumulate in the brain, which 
results in Alzheimer disease (69). Manipulation of these ef-
flux transporters can lead to either increased or decreased 
clearance of Aβ from the brain. Rifampicin and caffeine, 
which are two compounds that up-regulate p-gp activity, 
were shown to increase the clearance of Aβ from the brain 
(70). On the other hand, knockout of two efflux transport-
ers p-gp and BCRP increased the amount of Aβ within the 
brain (71).
There is a considerable overlap of Alzheimer disease and 
normal pressure hydrocephalus, with some authors re-
porting nearly 50% of patients with probable NPH hav-
ing evidence of AD (72). Several studies have shown that 
these two diseases co-exist, and the presence of amy-
loid plaques in the brain tissues of patients with nor-
mal pressure hydrocephalus is indicative of poor 
prognosis for successful treatment of hydrocephalus (71-
75).Recently, positron emission tomography (PET) has 
been used to detect the presence of amyloid plaques in 
patients clinically suspected to have normal pressure hy-
drocephalus (76).
Macromolecules are transported out of the ventricles and 
the brain into the serum even in the presence of hydro-
cephalus. Clinical studies show that there are several endo-
biotics that are cleared from CSF into the serum and these 
include S-100b, GFAP, NSE, and MBP. Vascular endothelial 
growth factor (VEGF) is elevated in CSF of patients with hy-
drocephalus (77). VEGF was increased several fold in the 
CSF in experimental chronic hydrocephalus and the in-
crease was significantly correlated with ventricular volume 
(78). Excess VEGF in the CSF is known to decrease p-gp ac-
tivity, thus contributing to hydrocephalus (79).
Experimental evidence in models of congenital hydro-
cephalus further supports the role played by p-gp in the 
pathogenesis. P-gp expression in the subcortical white 
matter and periventricular tissues (paravascular pathways) 
of H-Tx rats was absent when compared to normal animals 
(80). In another study (81), H-Tx rats were also found to 
have reduced nasal lymphatic clearance of CSF, suggesting 
that the paravascular/lymphatic pathways were impaired. 
In support of our experimental model of hydrocephalus, 
dextrans are known to be substrates of p-gp and they are 
distributed along both the olfactory pathways as well as 
the paravascular pathways (82).
One of the most common causes of hydrocephalus is in-
traventricular hemorrhage (IVH). IVH is a cause of signifi-
cant morbidity and mortality as a complication of neonatal 
germinal matrix hemorrhage and adult intracerebral hem-
orrhage (83). IVH causes hydrocephalus in 25–50% of these 
individuals and results in additional damage to the brain 
(83). Despite the fact that the amount of blood in the ven-
tricles plays a role in the development of hydrocephalus, 
it is not known why some patients develop hydrocepha-
lus and some do not. The role played by p-gp as an efflux 
transporter can potentially explain this variability.
There is considerable variation of expression of pgp in gen-
eral population. P-gp is the gene product of MDR1 (AB-
CB1). The MDR1 gene is subject to single nucleotide poly-
morphisms, which is associated with decreased function 
of p-gp between individuals (84). A well-known example 
of this variability affecting function is in relation to the opi-
ate analgesics.
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Mu opioid receptor agonists have identical target receptor 
affinities adjusted for dose (85). Despite this characteristic, 
individual opioids exhibit a marked variation in their abil-
ity to induce clinically-relevant analgesia despite equipo-
tent mu opioid receptor doses administered systemically, 
a characteristic that is explained entirely on the basis of the 
affinity of p-gp for an individual opioid (analgesia is inverse-
ly proportional to the affinity of the p-gp efflux transporter 
for the substrate drug) (86). Hence, loperamide, a potent 
mu opioid receptor agonist, does not produce either eu-
phoria or analgesia, being marketed over-the-counter in 
the USA as an antidiarrheal preparation, due to its local in-
hibition of gut motility (88). Evidence that loperamide has 
in vivo potent mu opioid agonist properties in the brain 
and that this effect is solely due to p-gp efflux has been 
clearly supported by pretreatment with a potent p-gp in-
hibitor prior to loperamide administration (87).
It is still unclear why some patients with IVH develop hydro-
cephalus and others do not. One of the possible explana-
tions is that there are genetic differences between individu-
als in how well they clear the blood and the blood products 
from the ventricles. Based on the discussions above, we 
hypothesize that if a patient has a genetic variant with de-
creased functionality of p-gp, then the potential for elimi-
nating macromolecules from the ventricles will be reduced 
in the presence of IVH, resulting in hydrocephalus.
In conclusion, hydrocephalus results from abnormal os-
motic gradients that favor water transport into the ven-
tricles. These abnormal gradients are due to a change in 
the macromolecular and ionic content in the ventricular 
CSF. Efflux transporters, in particular p-gp, play a key part in 
the clearance of macromolecules, both endogenous and 
exogenous, out of the ventricles and the brain, thus main-
taining the milieu interior. We have summarized existing 
literature with reference to p-gp and provided a context 
for focusing on this transporter with regards to hydroceph-
alus. However the details regarding the exact role played in 
hydrocephalus are yet to be clarified.
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